Literature DB >> 31149057

THE ROLE OF ADIPONECTIN AND TOLL-LIKE RECEPTOR 4 GENE POLYMORPHISMS ON NON-PROLIFERATIVE RETINOPATHY IN TYPE 2 DIABETES MELLITUS PATIENTS. A CASE-CONTROL STUDY IN ROMANIAN CAUCASIANS PATIENTS.

C S Aioanei1, R F Ilies1, C Bala2, M F Petrisor1, M D Porojan3, R A Popp1, A Catana1.   

Abstract

CONTEXT: Persistent inflammation and impaired neovascularization are important contributors to the development of diabetic retinopathy (DR). Gene polymorphisms of adiponectin (APN) were demonstrated to have an important role on the plasma level and activity of adiponectin. APN has anti-inflammatory, anti-diabetic and anti-atherogenic properties. Toll-Like Receptor 4 (TLR4) is a critical mediator of innate immunity. Polymorphisms in TLR-4 gene were shown to be associated with impaired inflammatory response in diabetes.
OBJECTIVE: The aim of the study was to analyze the association of +276G>T variant of APN gene and Asp299Gly and Thr399Ile of TLR-4 gene variants in relationship with T2DM and DR in an Eastern European population group.
DESIGN: The distribution of the mutant alleles in 198 T2DM patients with DR and 200 non-T2DM controls was examined. Genomic DNA from T2DM patients and healthy controls genotyped through the use of PCR-RFPL assay.
RESULTS: Genotype and allele frequencies of the Asp299Gly and Thr399Ile polymorphisms differed between T2DM patients and non diabetic subjects (P<0.001). Moreover, the presence of the minor alleles of these polymorphisms were significantly identified as protective factors against T2DM, under a dominant model of Fisher's exact test (χ2=4.988, phi=0.745, OR=0.767, 95% CI=0.602-0.867, P<0.001; respectively χ2=5.254, phi=0.820, OR=0.487, 95% CI=0.211-0.648, P<0.001). Genotype analysis for the adiponectin 276G>T gene polymorphism yielded no significant association with T2DM, but revealed a borderline significance for the association with DR (χ2=5.632, phi=0.423, OR =1.101, 95% CI=0.887-1.203, P=0.009).
CONCLUSIONS: We found an association between the TLR4 Asp299Gly and Thr399Ile polymorphisms and protection for DR. The APN genetic polymorphism is not associated with T2DM.

Entities:  

Keywords:  Adiponectin; Toll-like receptor 4; Type 2 diabetes mellitus; case-control study; diabetic retinopathy; single nucleotide polymorphisms

Year:  2019        PMID: 31149057      PMCID: PMC6535313          DOI: 10.4183/aeb.2019.32

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  31 in total

Review 1.  Genomics, type 2 diabetes, and obesity.

Authors:  Mark I McCarthy
Journal:  N Engl J Med       Date:  2010-12-09       Impact factor: 91.245

Review 2.  Statistical methods in genetics.

Authors:  Giovanni Montana
Journal:  Brief Bioinform       Date:  2006-09       Impact factor: 11.622

3.  TLR4 links innate immunity and fatty acid-induced insulin resistance.

Authors:  Hang Shi; Maia V Kokoeva; Karen Inouye; Iphigenia Tzameli; Huali Yin; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

Review 4.  Glycemic control and complications in type 2 diabetes mellitus.

Authors:  Mark Stolar
Journal:  Am J Med       Date:  2010-03       Impact factor: 4.965

5.  Adiponectin as a biomarker of clinical manifestation of metabolic syndrome.

Authors:  Mária Tajtákova; Darina Petrásova; Jozefína Petrovicová; Marek Pytliak; Zuzana Semanová
Journal:  Endocr Regul       Date:  2006-03

6.  Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway.

Authors:  N Ouchi; S Kihara; Y Arita; Y Okamoto; K Maeda; H Kuriyama; K Hotta; M Nishida; M Takahashi; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Funahashi; Y Matsuzawa
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

7.  Basic statistical analysis in genetic case-control studies.

Authors:  Geraldine M Clarke; Carl A Anderson; Fredrik H Pettersson; Lon R Cardon; Andrew P Morris; Krina T Zondervan
Journal:  Nat Protoc       Date:  2011-02-03       Impact factor: 13.491

8.  Association of +45G15G(T/G) and +276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women.

Authors:  Ning Zhang; Yu-Hua Shi; Cui-Fang Hao; Harvest F Gu; Yuan Li; Yue-Ran Zhao; Lai-Cheng Wang; Zi-Jiang Chen
Journal:  Eur J Endocrinol       Date:  2008-02       Impact factor: 6.664

Review 9.  Adiponectin as an anti-inflammatory factor.

Authors:  Noriyuki Ouchi; Kenneth Walsh
Journal:  Clin Chim Acta       Date:  2007-02-02       Impact factor: 3.786

10.  Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention.

Authors:  Alaa Badawi; Amira Klip; Pierre Haddad; David Ec Cole; Bibiana Garcia Bailo; Ahmed El-Sohemy; Mohamed Karmali
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-26       Impact factor: 3.168

View more
  5 in total

Review 1.  Role of HMGB1 signaling in the inflammatory process in diabetic retinopathy.

Authors:  Jena J Steinle
Journal:  Cell Signal       Date:  2020-06-01       Impact factor: 4.315

2.  Quantitative assessment of TLR4 gene polymorphisms and T2DM risk: A meta-analysis.

Authors:  Jinzhuo Fan; Renxian Liang
Journal:  Mol Genet Genomic Med       Date:  2020-08-21       Impact factor: 2.183

3.  Loss of TLR4 in endothelial cells but not Müller cells protects the diabetic retina.

Authors:  Adam Seidel; Li Liu; Youde Jiang; Jena J Steinle
Journal:  Exp Eye Res       Date:  2021-03-28       Impact factor: 3.467

4.  RETINAL MICROCIRCULATION INVESTIGATION IN TYPE I AND II DIABETIC PATIENTS WITHOUT RETINOPATHY USING AN ADAPTIVE OPTICS RETINAL CAMERA.

Authors:  I E Cristescu; L Zagrean; F Balta; D C Branisteanu
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

5.  Meta-analysis of the association between adiponectin SNP 45, SNP 276, and type 2 diabetes mellitus.

Authors:  Yuwei Dong; Gongping Huang; Xin Wang; Zhaoming Chu; Jingzhi Miao; Houwen Zhou
Journal:  PLoS One       Date:  2020-10-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.